Background: Long non-coding RNA (lncRNA) has emerged as a new avenue of interest due to its various biological functions in cancer. Abnormal expression of lncRNA has been reported in other malignancies but has been understudied in head and neck squamous cell carcinoma (HNSCC).
| I NT ROD UCTI ON
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type worldwide and accounts for approximately 350 000 deaths per year. 1, 2 Risk factors, such as tobacco, alcohol use, and, more recently, human papillomavirus (HPV) have been identified as etiological factors in the occurrence of HNSCC. Despite advances in the treatment of localized HNSCC, approximately half of the patients will develop recurrent disease, 3 which is a major contributor to patient mortality. In addition, HPV-positive and HPVnegative HNSCC are biologically distinct with the latter being associated with poorer prognosis. Unlike other malignancies, there are no tools in widespread use that can identify early disease and there is no systematic approach that has proven effective in monitoring for early evidence of recurrence. Hence, novel markers are needed that appropriately characterize those patients with early-stage disease as well as identify and characterize the response of individual patient's treatment.
Although only 1.2% of our DNA sequence encodes proteins, approximately 75% of the human genome is capable of being transcribed into RNA, 4 and it has become increasingly apparent that RNA plays a diverse and important role in genome integrity through production of both proteins as well as non-coding RNA (ncRNA), including long non-coding RNA (lncRNA). Whereas the microRNA class of ncRNA has been widely studied in the context of cancer, lncRNA, which are larger (>200 bases and approximately 1-2 exons in length) 5 and have a more complex secondary/tertiary structure, have recently begun to garner increased attention. 6 This is largely due to their diverse biological functions, 7 which can include inhibition of target gene transcription, initiation of alternative splicing, generation of protein scaffolding and chromatin organization, and alteration of transcription factor activity. Even though 18 000 human long non-coding human transcripts have been catalogued in GENCODE version 7, 4 the lncRNA Database (http://www.lncrnadb.org), a database of functionally annotated eukaryotic lncRNA, only contains information for 127 human lncRNA, highlighting the gap in our knowledge of lncRNA biology. Identification of lncRNA transcripts that are associated with human diseases and the corresponding pathobiology (e.g. aggressiveness or responsiveness to treatment) would, therefore, provide a welcome means for prioritizing functional studies. Several lncRNA have recently been reported to be differentially expressed in various cancers and to play a role in cancer growth, invasion, epithelial-to-mesenchymal transition, motility, and metastatic potential 8, 9 and, as such, are increasingly recognized as having a very strong potential as cancer biomarkers. 10 Several recent studies have reported that higher expression of lncRNA, such as HOX antisense intergenic RNA (HOTAIR) and metastasis associated lung adenocarcinoma transcript 1 (Malat-1), is associated with invasion and metastasis in various epithelial cancers, [11] [12] [13] [14] [15] [16] [17] although the prognostic significance of lncRNA in HNSCC has been understudied to date. The purpose of this study was to identify differentially expressed lncRNA in HPV-negative HNSCC and assess its impact on outcomes in these groups of patients. 
| MA TERI A LS AND M ETH ODS

| Tumor samples
| Differential expression
Expression was normalized to the geometric mean of 5 housekeeping control genes: ACTB; B2M; RPLP0; RN7SK; and SNORA73A. Differential expression of each lncRNA was described in terms of fold-change for tumors relative to adjacent normal tissue based on a 1-sample t test, adjusted for multiple testing by false discovery rate estimation and Q values using the methods proposed by Benjamini and Hochberg. 18 Expression was considered significantly differential where Q 0.1.
| Replication using The Cancer Genome Atlas RNA-sequencing data
The RNA-seq data in the form of bam files of aligned reads was obtained for head and neck cancers in TCGA project were downloaded from the Cancer Genomics Hub. Reads not mapped to the human genome were aligned to HPV16 (NC_001526) E6 and E7 viral oncoprotein transcript sequences using bowtie aligner. 19 HPV status was inferred by designating the sample to be from an HPV-positive tumor if >1000 reads mapped to HPV oncoproteins and an HPVnegative tumor otherwise. The harmonized read counts for TCGA head and neck samples aligned to lncRNA defined in the GDC.h38 GENCODE version 22 GTF file were downloaded from the National Cancer Institute (NCI) Genomic Data Commons 19 using the TCGAbiolinks Bioconductor package. 20 Normalized counts (count per million) for each of the 7 lncRNA in each sample were calculated using the cpm function in the Bioconductor package edgeR. 21 Since the distributions of lncRNA expression were nonlinear, differential expression was assessed nonparametrically using the Wilcoxon rank sum test, comparing tumor expression (n 5 444) to that of all available normal samples (n 5 44), and was considered differential where P .05. Median foldchange was determined for each tumor by comparing its expression to the median expression of the normal samples. A description of the distribution of expression values for the 7 lncRNA in the 44 adjacent normal samples is provided in Supporting Information Table S2 .
| Survival analysis using The Cancer Genome Atlas samples
To visualize the 5-year overall survival (OS) and 3-year recurrence-free survival (RFS), univariate Kaplan-Meier and cumulative incidence (to account for death as a competing risk 22, 23 ) functions were generated, respectively, comparing curves for low, normal, and high expression levels. Discrete multivariable Cox proportional hazards and cumulative incidence models were fit to assess 5-year OS and 3-year RFS, respectively, for each of the significant lncRNA, adjusted for age, sex, race, smoking status, tumor site, and stage at diagnosis, as established a priori. Missing values of model covariates were imputed (m 5 20) using multivariate normal regression, based on age, sex, stage, and primary tumor site. Log-log plots (ie, -log(-log (S(t))) vs log(t)) were generated for each model to verify that the proportional hazards assumption was met. Statistical analyses were conducted using Stata 13 (Stata Corp, College Station, TX). All statistical tests were 2-sided, and significance was considered when the unadjusted P .05.
| R ES ULT S
The median age for the UCCI cases (n 5 19 tumor-normal pairs) was 64 years, 74% of which were men. The UCCI and TCGA sets differed in terms of smoking status (P 5 .01), with fewer nonsmokers in the UCCI set but were comparable in terms of age, sex, race, primary tumor site, American Joint Committee on Cancer (AJCC) stage group, and tumor grade ( Table 1 ). The majority of tumors in both sets originated in the oral cavity (63% and 66%, respectively), and presented at an advanced stage (III or IV).
Eleven of the lncRNA included on the array were not detected in any of the tumor or normal samples (Supporting Information Table S1 ). Twenty lncRNA were significantly differentially expressed at a nominal P value .05 (8 upregulated and 12 downregulated). After false discovery rate adjustment, 7 lncRNA remained significantly differential (Q 0.1: SPRY4-IT1, HEIH, LUCAT1, LINC00152, and HAND2-AS1, MEG3, and TERC; 4 upregulated and 3 downregulated; Table 2 ). Expression of these 7 lncRNA was also significantly differential for 5 of the 7 lncRNA in the TCGA validation set (SPRY4-IT1, HEIH, LUCAT1, LINC00152, and HAND2-AS1). It should be noted, however, that although MEG3 and TERC were not significantly differentially expressed in the TCGA validation set, there was wide variability in terms of expression in both directions (i.e., upregulation and downregulation) for individual tumors relative adjacent normal samples ( Figure 1B) . Interestingly, black patients in the TCGA dataset were significantly more likely to exhibit high (>2-fold) and low (<0.5-fold) MEG3 expression (Table 3) .
The relationship between each of the 7 lncRNA and 5-year OS and 3-year RFS was assessed using the TCGA dataset. Among the 7 lncRNA identified, only differing levels of MEG3 had an impact on 3-year RFS. Patients with low MEG3 expression (<0.5 fold change) were found to have a significantly lower 3-year RFS, whereas higher MEG3 expression (>2-fold change) seemed to have better 3-year RFS, although this did not reach statistical significance Abbreviations: lncRNA, long non-coding RNA; qPCR, quantitative polymerase chain reaction; RNA-seq, RNA-sequencing; TCGA, The Cancer Genome Atlas. Q value significant at Q < 0.01.
( Figure 2 and Table 4 ). We also analyzed the associations between the 7 lncRNA and clinical characteristics of HPVnegative HNSCC in TCGA and found that low MEG3 expression was associated with locally advanced disease and low expression of HANDS-2AS1 correlated with more locally advanced cancer, although this did not seem to have an impact on survival outcomes. Restriction of the differential expression analysis to the 44 tumor-normal pairs in the TCGA validation set yielded similar results (data not shown).
| DI S CU S S IO N
There is increasing evidence that aberrant expression of lncRNA plays a role in the genesis and progression of HNSCC. 24, 25 Through our present study, we were able to identify and validate 5 differentially expressed lncRNA in HPV-negative HNSCC (SPRY4-IT1, HEIH, LUCAT1, LINC00152, and HAND2-AS1). Further, we found that low expression of MEG3 was associated with more favorable 3- 
year RFS, although the significance of this finding is unclear.
MEG3 is a lncRNA located at the DLK-MEG3 locus on chromosome 14q32.3 and is reported to be a tumor suppressor gene, exerting its effect in part through interaction with tumor suppressor and master regulator p53. 26, 27 MEG3 has been reported to be downregulated in multiple solid tumor types, 28 which is consistent with what we observed in our 19
HPV-negative HNSCC tumor-adjacent normal pairs. However, our observed association of low MEG3 expression with better 3-year RFS is contrary to what has been reported for other solid tumor types 29 and, therefore, should be interpreted with caution. In particular, Jia and colleagues 30 found that low expression of MEG3 correlated with poorer outcomes in squamous cell carcinoma (SCC) of the anterior tongue, and overexpression of MEG3 inhibited cell proliferation and cell cycle progression in SCC-15 and Cal 27 tongue SCC lines. Although the other differentially expressed lncRNA transcripts in our study were not associated with OS or RFS in the TCGA head and neck tumors, they have been identified as potential markers for poor prognosis in other cancer types. SPRY4-IT1, which is located on the SPRY4 gene, has been implicated in cell growth invasion and increased apoptosis, 31 and elevated expression of SRPY4-IT1 has been associated with poorer outcomes in esophageal SCC, which, like HPVnegative HNSCC, is also strongly associated with tobacco and alcohol. 32 Overexpression of HEIH has been reported in hepatocellular carcinoma, in which it is an independent predictor for recurrence and survival and interacts with the lysine methyltransferase and Polycomb Repressor Complex 2 member Enhancer of Zeste Homolog 2 (EZH2). 33 Upregulation of both LUCAT1 and LINC00152 have been associated with poorer outcomes for non-small cell lung cancer, 34, 35 and HAND2-AS1 has been reported to be upregulated in stage IV-S neuroblastoma 36 but downregulated in metastatic hepatocellular carcinoma, 37 with the latter being more in-line with our narrative of lower expression of HAND2-AS1 in HPV-negative HNSCC. Strengths of our study include the comprehensive assessment of 84 cancer-associated lncRNA and our ability to access raw RNA-seq data from TCGA. This allowed the alignment of our data with annotated lncRNA sequences to validate our findings in an independent dataset and assess the impact of significantly differential lncRNA on OS and RFS, and to infer HPV status by aligning to HPV16 E6/E7 viral mRNA transcripts. Our study also has several limitations, including the modest sample size of our initial discovery set, which may have adversely impacted our power to detect smaller effect sizes, increasing the risk of false-negative results. However, our use of a stringent false discovery ratecontrol and validation in an independent set of tumors using TCGA data yields high confidence in our significant results. Furthermore, because no adjustments were made for multiple comparisons in the survival analyses, we cannot rule out the spurious nature of the observed association between MEG3 and RFS. Additionally, use of archival formalin-fixed paraffin-embedded tissue for our discovery set likely attenuated the lncRNA expression levels, which could reduce our sensitivity for detection of signal or more subtle differences in expression. Our use of the RNeasy formalin-fixed paraffinembedded kit, which is specifically engineered to maximize the integrity and downstream results for RNA extracted from formalin-fixed paraffin-embedded, 38 helps mitigate this issue; it is also notable that 5 of the 7 differentially expressed lncRNA identified with the array were replicated using RNA-seq data from fresh tissue, supporting the validity of our findings.
| C ONCL US I ON
Expression of lncRNA is dysregulated in HPV-negative HNSCC. Specifically, we have identified and validated 5 differentially expressed lncRNA: SPRY4-IT1, HEIH, LUCAT1, LINC00152, and HAND2-AS1. Additional studies are needed to confirm the potential prognostic value of MEG3 expression in HNSCC.
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